FinanceLinkway

Let's look at some biotech companies with stable cash flow and currently undervalued value stocks as targets for diversified portfolios.  The company I shared today, called Vertex Pharmaceuticals (VRTX), is dedicated to the development of rare diseases, especially Cystic Fibrosis (CF). I have always had high respect for the rare disease group of pharmaceutical companies in the disease category. In addition, in the future, gene and cell therapies are subverting the role of rare diseases in the pharmaceutical industry, making rare diseases no longer uncommon. It's tasteless, but a field full of the future. Vertex Pharmaceuticals Inc. was established in 1989 by Joshua Boger and Kevin Kinsella. is headquartered in Boston. At that time, several very good research and development companies were established in the United States, including the aforementioned Regeneron, Gilead, and today's Vertex.  Vertex In the past, he devoted himself to the development of small molecule drugs, wh...

When Cathie Wood buys stocks, investors will follow her to buy, which seems to be the latest trend in the investment world.  In the popular saying, following Cathie Wood, there is money to be made.  Even some time ago due to the rise in U.S. Treasury yields, technology stocks plummeted, and ARK funds suffered a frantic sell-off. Wood is still as stable as a mountain, and he issued a statement saying that everything was as early as we expected and was better than we expected.  Technology stocks are a good time to buy bottoms and increase positions.  Today, I will analyze Cathie Wood's heavy holdings from the company's fundamentals and future market prospects. Can it double in the long run?  Square (ranked first in ARKK's innovative technology ETF)  The financial technology giant Square is a revolutionary stock in the financial industry, breaking the traditional payment industry.  Square is known for its seller ecosystem, which provides small businesses ...